Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCL – OncLive

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

Lori A. Leslie, MD, a hematology/oncology specialist at John Theurer Cancer Center, discussesdevelopmentsin CAR T-cell therapy indiffuse large B-cell lymphoma (DLBCL)andmantle cell lymphoma (MCL).

A lot has been done with CAR T-cell therapy since the approval of axicabtagene ciloleucel (axi-cel; Yescarta) in 2017 for patients with relapsed/refractory DLBCL, says Leslie. Initial studies examined this approach in patients with DLBCL who were very refractory, were more appropriate for hospice than CAR T cells, and had aggressive lymphoma. Approximately 40% of patients experienced long-term complete remissions (CRs) or potential cure, which is impressive in a patient population that was expected to live less than 6 months, explains Leslie.

CAR T-cell therapy is moving earlier in the treatment journey for DLBCL. When a standard-of-care option is used, patients have usually received 2 prior lines of therapy, theyre not as refractory, and are in better shape to start CAR T-cell therapy; these patients have more flexibility to wait between T-cell collection and CAR T manufacturing, says Leslie.

Ongoing studies are looking at potentially replacing autologous stem cell transplant (ASCT) with CAR T cells, even in the second-line setting for patients who are at high risk of relapse within 1year of frontline therapy, adds Leslie. Trials are looking at randomizing patients to either CAR T-cell therapy or standard salvage ASCT in this setting. Similar studies are being conducted in the MCL space.

Development in low-grade lymphomas and MCL will be similar, Leslie adds. Brexucabtagene autoleucel (Tecartus; formerly KTE-X19) has been approved by the FDA for patients with relapsed/refractory MCL. Plans are underway to move this modality earlier on in the treatment journey, particularly in patients withp53-mutated abnormal MCL, blastoid MCL, orpleomorphic high-risk MCL. The goal is to eradicate minimal residual disease (MRD) after frontline treatment if patients do not experience an MRD-negative CR, says Leslie. Those are exciting research questions that will be answered in the near future, concludes Leslie.

Here is the original post:
Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCL - OncLive

From artificial lenses to stem cell techniques: these are the most important innovations in ophthalmology – Innovation Origins

Our professional field is constantly evolving, says Professor Carroll Webers. He is head of the University Clinic for Ophthalmology at Maastricht UMC+ in the Netherlands, where he started in 1993 as an ophthalmologist with glaucoma (high eye pressure) as a special focus area. Since then, the field has been expanding rapidly and encompasses a wide range of applications for patients. Such as treatments for eye disorders caused by diabetes, retinal detachment, glaucoma, and macular degeneration (which is an age-related phenomenon that affects the retina).

Technological developments play a key role in what can be achieved in ophthalmology. Webers gives a brief glimpse into how the Maastricht university clinic is contributing to these developments.

Notably with the research on stem cell technique carried out by his colleague Professor Rudy Nuijts, for example. A technique that is especially interesting for people who have become blind in one eye as a result of a burn or a caustic substance in the eye.

Together with the Italian cell biologistGraziella Pellegrini and the company Chiesi Pharmaceuticals, Nuijts developed a technique whereby stem cells from the healthy eye are used to grow a new membrane. Nuijts extracts the stem cells which are then sent by courier to Italy. There, Pellegrini cultivates these cells, which takes about two weeks. After that, they are returned to the Maastricht UMC+ as a new membrane. Nuijts subsequently attaches this to the damaged eye. In the Dutch television program Dokters van Morgen (Doctors of Tomorrow), they show how Anne-Mieke King is able to see again after being blind in one eye for many years.

A groundbreaking innovation, Webers declares, but not one that many people will have to undergo. That certainly is the case for cataract operations. At a later age, plenty of peoples own lenses become cloudy, which is what we call a cataract. In the Netherlands, cataract surgery is carried out about 180,000 times a year. The blurred lens is then replaced by an artificial lens. Up until the 1990s, the incision had to be at least as large as the own lens, about 10 millimeters, and that had to be stitched up again. Webers: In general, the smaller the surgical procedure, the faster the patients recovery. With laser techniques, we only need an opening of 1.6 millimeters to replace the blurred lens. Because the incision is so small, stitches are no longer necessary.

I always joke with my patients by saying that both their eyes are about the same age. That implies that they have cataracts in both eyes. For years, the guideline was that one eye was operated on first and after two weeks, the other eye followed. Recently, the Maastricht UMC completed a study showing that it is possible to operate both eyes at once.

You first operate on one eye. Then you take a totally new set of instruments, new fluids, a new jacket, new gloves, and you operate on the other eye. Since July, patients can come to Maastricht UMC+ for this double-sided operation. This has been stepped up in part due to corona. Because in this corona crisis you naturally want patients to be hospitalized as little as possible. If you operate them separately on both eyes, they will just end up coming to the hospital twice as often.

Patients not only need to be examined less often, but it also makes a difference in terms of home care, Webers notes. After this kind of operation, patients have to have eye drops. A substantial proportion of this is done by home care services. Initially, patients have to get drops four times a day for a week, then three times a day for a week, then twice a day for a week, and then once a day for a week. If that can be done with two eyes at the same time, it would make a huge difference.

His original specialism, glaucoma, is also advancing. Every eye has a certain pressure by nature. An eye would never be a beautiful ball otherwise. With glaucoma, the pressure is in principle too much for that eye and in the long run, this leads to irreparable damage. In the end, the patient becomes visually impaired and blind.

There are approximately 350,000 people in the Netherlands who are walking around with glaucoma, Webers adds. High eye pressure can be treated with eye drops, laser surgery, and minor surgical procedures. But the real innovation is a very small stent, which you can also insert into a blood vessel. The hollow tube makes it easier for fluid to drain away, Webers goes on to explain. A project is being carried out by the University Clinic for Ophthalmology at Maastricht UMC+ in conjunction with the Brightlands Campus Chemelot. Ophthalmologist Henny Beckers is in charge of the project.

Finally, Webers goes on to talk a little about his hobby. You dont really know in advance how sensitive a patient is to that eye pressure. The problems only manifest themselves at a later stage. If I knew how sensitive someone is, I might or might not opt for a more intensive treatment. In order to gain more understanding of that sensitivity, the clinic collects body tissue from all glaucoma-compatible patients for research. Of course, we ask for permission to store blood and the tissue and fluid thats lost during surgery. The eye tissue bank now contains samples from around 1500 patients.

Webers explains that you can make blood cells, stem cells, and optic nerve cells from those stem cells. You have to do all sorts of things to achieve this. But it can be done. These cultivated optic nerve cells are put under pressure under laboratory conditions. We want to develop an instrument that allows us to show whether a patient is very sensitive to eye pressure or not. This will give us an insight into how great the risk is that that patient will become seriously visually impaired over the course of her or his life. Then you also have a better idea of how extensively you should treat them.

In addition to sensitivity, Webers also hopes to gain a deeper understanding of what the innate protective factors are. It could be your genes or your diet, for example. You could add protective substances to the cultivated optic nerve cells to see if that cell would then become less vulnerable, Webers continues. Those substances can vary a lot from one individual to another. You may be sensitive to all sorts of substances contained in green vegetables, whereas I am not at all. In that case, the advice would be: Take nutritional supplements. And for me: Dont do that. To us, this is Personalized Medicine. Highly innovative but still at an experimental stage.

This article is a follow-up to: Electronic lens offers a medical solution for eye disorders.

See the original post here:
From artificial lenses to stem cell techniques: these are the most important innovations in ophthalmology - Innovation Origins

The global market for Nerve Repair and Regeneration is projected to reach US$12.7 billion by 2025 – GlobeNewswire

September 29, 2020 02:35 ET | Source: ReportLinker

New York, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Devices Industry" - https://www.reportlinker.com/p05957490/?utm_source=GNW Nerves constitute the most significant cable systems in the human body, performing the crucial job of carrying messages and information to brain and also to other parts of body. Whenever such critical nerves are injured, problems arise in muscles leading to sensation loss. Major types of nerve injuries include Neuropraxia, the physiologic blocking of nerve; Axonotmesis, the anatomic disruption of axon with slight disruption of connective tissue; and Neurotmesis, the anatomic disruption of connective tissue and nerve fibers.These injuries could result in trauma or more serious neurodegenerative diseases such as Parkinson`s disease, Alzheimer`s disease, multiple system atrophy, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig`s disease).Alzheimer`s, Parkinson`s, Amyotrophic Lateral Sclerosis and multiple sclerosis are diseases that cause injury to the complex, delicate structures of the nervous system.Till date spinal cord injury and peripheral nerve damage are often permanent and incapacitating.

Innovative strategies are required for a shift in the paradigm and advanced treatment of these neurological injuries.But the question as to whether adult neurogenesis isrealstill remains unanswered with several contentious research studies still underway with no definitive answer to this century-long debate. Regrowth or repair of nervous tissues and cells involves generation of new neurons, glia, axons, myelin, or synapses.Gene Therapy is attracting immense research investments for its promise in promoting nerve regeneration and intraneural revascularization is being studied for its role in peripheral nerve regeneration.Newer studies are however dampening hopes by stating that adults produce no new cells in the hippocampus. Nevertheless, hopes of regeneration arecreating lucrative commercial opportunities as the pressure builds for newer and more effective treatment for neurological diseases.As the world awaits for a paradigm-shift in the treatment of neurological injury, neurostimulation and neuromodulation devices and biomaterials remains a massive multi billiondollar market worldwide. Neurostimulation and neuromodulation devices are currently available solutions to treat a variety of nerve injuries including peripheral nerve injuries. Neurostimulation and neuromodulation methods involve use of specially designed devices to transmit electrical impulses for controlling activity of the central nervous system and the brain.Internal neurostimulation and neuromodulation devices are growing in popularity for their significantly lower risk for post-surgical complications and shorter hospital stays. These include deep brain stimulation (DBS)for Parkinson`s, epilepsy and depression; spinal cord stimulation (SCS) for pain management and spasticity; gastric electrical stimulation (GES) for obesity and gastroparesis; vagus nerve stimulation (VNS) for depression and epilepsy; and sacral nerve stimulation (SNS) for constipation and urinary incontinence disorders.External neurostimulation devices, on the other hand, comprise transcutaneous vagus nerve stimulation (TVNS) for autism, depression, anxiety and age related disorders; transcutaneous electrical nerve stimulation (TENS)for chronic neuropathic pain and fibromyalgia disorders; transcranial magnetic stimulation (TMS)for depression and ADHD; and respiratory electrical stimulation (RES) for improving the respiratory function after spinal cord injury.

Read the full report: https://www.reportlinker.com/p05957490/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW Nerve Repair and Regeneration Market Set for a Rapid Growth Neurostimulation and Neuromodulation Devices: Largest Product Segment Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market, Asia-Pacific to Register the Fastest Growth

2. FOCUS ON SELECT PLAYERS Abbott Laboratories, Inc. (USA) AxoGen, Inc. (USA) Boston Scientific Corporation (USA) Integra LifeSciences Corporation (USA) LivaNova, PLC (UK) Medtronic plc (USA) NeuroPace, Inc. (USA) Nevro Corporation.(USA) Orthomed S.A.S. (France) Polyganics B.V. (The Netherlands) Stryker Corporation (U.S.) Synapse Biomedical Inc. (U.S.)

3. MARKET TRENDS & DRIVERS High Incidence of Brain Disorders and Nerve Injuries: Primary Market Driver Annual Incidence of Adult-Onset Neurologic Disorders in the US Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy Global Alzheimers Prevalence by Age Group Diagnosed Prevalence Cases of Parkinson?s Disease Across Select Countries Classification of Nerve Injuries Recent Developments in Spinal Cord Injury Treatment Rising Geriatric Population and Subsequent Growth in Prevalence Of Neurological Disorders Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker Technological Advancements and Product Innovations - A Key Growth Driver Neurostimulation Allows Paralyzed People to Regain Leg Movement Neurostimulator to Treat Neurological Conditions Micro-Implantable Solution for Neurostimulation Parasym? Device for Neurostimulation Boston Scientific?s Spinal Cord Stimulation Improves Quality of Life Intellis? Platform Presents Smallest Implantable Neurostimulator Innovation in Deep Brain Stimulation for Parkinson?s Disease Innovations in Spinal Cord Stimulation for Pain Smart Neuromodulation: The Combination of AI and Neuromodulation Technologies New Dynamic Lead Interface Design for Neurostimulator Devices Wireless SCS Neuromodulation Therapy: An Alternative to Traditional SCS System Select Recent Approvals of Neuro-stimulation and Neuromodulation Devices Select Launches in Spinal Cord Stimulation (SCS) Market Select Launches in Deep Brain Stimulation (DBS) Market Select Neurostimulation Devices in Clinical Trials Select Neuromodulation Devices in Clinical Trials

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 2: World Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 3: World 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 5: World Historic Review for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 6: World 15-Year Perspective for Neurostimulation & Neuromodulation Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 8: World Historic Review for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 9: World 15-Year Perspective for Biomaterials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 11: World Historic Review for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 12: World 15-Year Perspective for Neurostimulation & Neuromodulation Surgeries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 14: World Historic Review for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 15: World 15-Year Perspective for Neurorrhaphy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 17: World Historic Review for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 18: World 15-Year Perspective for Nerve Grafting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 20: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 21: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 23: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 24: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 26: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 27: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES Table 28: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 29: USA Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 30: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 31: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 32: USA Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 33: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 35: USA Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 36: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CANADA Table 37: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 38: Canada Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 39: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 40: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 41: Canada Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 42: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 43: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 44: Canada Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 45: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

JAPAN Table 46: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 47: Japan Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 48: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 49: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 50: Japan Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 51: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 52: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 53: Japan Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 54: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CHINA Table 55: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 56: China Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 57: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 58: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 59: China Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 60: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 61: China Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 62: China Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 63: China 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

EUROPE Table 64: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 65: Europe Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 66: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 67: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 68: Europe Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 69: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 70: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 71: Europe Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 72: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 74: Europe Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 75: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

FRANCE Table 76: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 77: France Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 78: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 79: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 80: France Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 81: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 82: France Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 83: France Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 84: France 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

GERMANY Table 85: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 86: Germany Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 87: Germany 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 88: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 89: Germany Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Here is the original post:
The global market for Nerve Repair and Regeneration is projected to reach US$12.7 billion by 2025 - GlobeNewswire

Stem Cell Market By Applications, Types, New Technology Opportunity Analysis And Forecast: 2020 2028 – The Daily Chronicle

Latest Market Scenario for Stem Cell Market

The major objective of the report is to offer a complete evaluation of the Stem Cell market and crucial insights, historical data, industry-validated market data, facts, and policies with a suitable set of assumptions and methodology. The report also analyses the Stem Cell market in a dynamic structure by studying and identifying the market segments and forecast for the global market size. Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-40210?utm_source= dc/hp

In addition, the report emphasizes the competitive analysis of key players by-product, growth strategies, financial position, price, product portfolio, and regional existence. The report also offers PEST analysis, SWOT analysis, and PORTERs analysis to address the questions of shareholders.

Stem Cell Market

Global Stem Cell Market Size and Scope:

The global Stem Cell market is segmented by company, type, application, by region, by country, and by sales channels. Industry players, stakeholders, and other market contributors in the global market will be able to increase their efficiency, as they can use the analysis as a powerful resource. Moreover, the segmental analysis emphasizes on sales, revenue, and estimation by region, company, type, application, by country, and by sales channels for the period 2016-2028. The global Stem Cell market is segmented as By Source (Adult Stem Cell, Human Embryonic Cell, Pluripotent Stem Cell, and Others), By Application (Therapeutic and Drug Development and Discovery), By Treatment Type (Allogeneic, Autologous, and Syngeneic), By Stem Cell Banking (Service & Technology and Banking Type). In terms of geographical regions, the market is segregated into North America, Asia Pacific, Europe, and the Middle East and Africa and South America.

Get ToC for the overview of the premium report https://www.quincemarketinsights.com/request-toc-40210?utm_source=dc/hp

Competitive Scenario of the Global Stem Cell Market

The Stem Cell Market report presents several major manufacturers in the industry. The study offers a big microscopic look into the target industry. The reader can recognize the footprints of the industries by knowing the global market share of manufacturers, the global price of manufacturers, and sales by providers over the forecast period. It helps the client understand the strategies and acquisitions that providers can leverage in order to combat competition in the industry. The key players of the automotive automatic transmissions have been provided in the report. These include Thermo Fisher Scientific, Qiagen NV, Sigma Aldrich, Becton, Dickinson and Company, and Stem Cell Technologies

The Stem Cell Market is studied by market experts by keeping in mind how to boost the return on investment by offering clear data required for informed business decisions. It illuminates the competitive scenario, the supply and demand status, and the challenges for market growth, market opportunities, and the threats faced by the key players.

Speak to analyst before buying this report https://www.quincemarketinsights.com/enquiry-before-buying-40210?utm_source=dc/hp

The recent trends observed in the target market, owing to the emergence of advanced technologies implemented in the Stem Cell Market, have been studied in detail. This research will help both developed and novel competitors to identify and analyze market essentials, market size, and competition. The report evaluates the growth rate and the precise market value based on the growth-inducing factors and market dynamics. The complete knowledge is based on recent news, opportunities, and recent trends presented in the report.

Highlights Covered in Global Stem Cell Market Report:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Read more from the original source:
Stem Cell Market By Applications, Types, New Technology Opportunity Analysis And Forecast: 2020 2028 - The Daily Chronicle

Cell Freezing Media for Cell Therapy Market Development Factors and Investment Analysis by Leading Manufacturers: BioLife Solutions, Thermo Fisher…

Los Angeles, United State: The global Cell Freezing Media for Cell Therapy market is comprehensive and accurately presented in the report with the help of detailed market information and data, critical findings, error-free statistics, and reliable forecasts. The report digs deep into important aspects of the global Cell Freezing Media for Cell Therapy market, including competition, segmentation, regional expansion, and market dynamics. Each leading trend of the global Cell Freezing Media for Cell Therapy market is carefully studied and elaborately presented in the report. This will help players to take advantage of opportunities available in the global Cell Freezing Media for Cell Therapy market and tap into new or unexplored ones in the near future. Readers are also provided with detailed information on key drivers and restraints of the global Cell Freezing Media for Cell Therapy market. Players can become informed about unknown future challenges in the global Cell Freezing Media for Cell Therapy market and prepare effective strategies to better deal with them.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/1776151/2149775/global-cell-freezing-media-for-cell-therapy-market

Both leading and emerging players of the global Cell Freezing Media for Cell Therapy market are comprehensively looked at in the report. The analysts authoring the report deeply studied each and every aspect of the business of key players operating in the global Cell Freezing Media for Cell Therapy market. In the company profiling section, the report offers exhaustive company profiling of all the players covered. The players are studied on the basis of different factors such as market share, growth strategies, new product launch, recent developments, future plans, revenue, gross margin, sales, capacity, production, and product portfolio.

Key Players Mentioned in the Global Cell Freezing Media for Cell Therapy Market Research Report: BioLife Solutions, Thermo Fisher Scientific, Merck, GE Healthcare, Zenoaq

Global Cell Freezing Media for Cell Therapy Market by Type: With FBS, Without FBS

Global Cell Freezing Media for Cell Therapy Market by Application: Human Embryonic Stem Cells, CAR-T Cell Therapy, Neural Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Hematopoietic Stem Cell Transplantation, Others

Players can use the report to gain sound understanding of the growth trend of important segments of the global Cell Freezing Media for Cell Therapy market. The report offers separate analysis of product type and application segments of the global Cell Freezing Media for Cell Therapy market. Each segment is studied in great detail to provide a clear and thorough analysis of its market growth, future growth potential, growth rate, growth drivers, and other key factors. The segmental analysis offered in the report will help players to discover rewarding growth pockets of the global Cell Freezing Media for Cell Therapy market and gain a competitive advantage over their opponents.

Key Questions Answered

Request for customization in Report: https://www.qyresearch.com/customize-request/form/2149775/global-cell-freezing-media-for-cell-therapy-market

Table of Contents

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Link:
Cell Freezing Media for Cell Therapy Market Development Factors and Investment Analysis by Leading Manufacturers: BioLife Solutions, Thermo Fisher...

2020 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Competitive Research, Top Companies, Key Types, Revenue, Share, Size…

"The niche and established Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market 2020 Covering Prime Players, Regions, Countries, And Growth Trends Forecast To 2026 is studied in this research report. The Industry dynamics with Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) future-proofing business plans are analyzed to offer sustainable growth for our clients. The insights-driven data covering the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) competition, product demand across different operating regions, countries, and a variety of applications are covered. Actionable insights offered by Reports Check will help achieve you in achieving exemplary growth with feasible investments. To strengthen the position in the global and domestic Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market revenue, size & share analysis, import-export details, production capacity, and utilization ratio is offered.

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is expected to reach XX.XX Mn USD by 2026 and it will capture lucrative opportunities with rising demand. The market dynamics, SWOT analysis, Porters Analysis, the risk assessment will create discerning growth and profit-driven strategies. Reports Checks analyst team is fine-tuned to answer all client queries and well as to deliver custom solutions based on their requirements.

Click Here To Receive FREE Sample Report Copy Or Send Any Custom Query/Requirements:https://www.reportscheck.com/shop/2021-2026-report-on-global-circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market-by-player-region-type-application-and-sales-channel/#sample-request

Study Period: 2015-2026

Base Year: 2019

Estimated Year With COVID-19 Impact Analysis:2020

Forecast Period Duration:2020-2026

Historical Period Duration:2015-2018

Important and Top Product Types:

CellSearch Others

By Various Applications:

Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment

By Top Companies On Global, Regional And Country Level:

Janssen Qiagen Advanced Cell Diagnostics ApoCell Biofluidica Clearbridge Biomedics CytoTrack Celsee Fluxion Gilupi Cynvenio On-chip YZY Bio BioView Fluidigm Ikonisys AdnaGen IVDiagnostics Miltenyi Biotec ScreenCell Silicon Biosystems

By Geographical Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Presence:

The current Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market landscape, detailed insights, and market drivers with restraints and trends are studied in this report. The detailed market performance during the forecast period is presented in this report. The Y-o-Y growth and CAGR is presented in this report to support the readers in making appropriate business plans. The quantitative development opportunities and innovations in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry are presented.

Click Here To Check Detailed Report Table of Contents With List of Figures/ Tables and Receive FREE Sample Report:https://www.reportscheck.com/shop/2021-2026-report-on-global-circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market-by-player-region-type-application-and-sales-channel/#table-of-contents

All details including Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market investors, manufacturers, service providers, distributors, stakeholders are provided. This research study by Reports Check helps the industry experts, researchers, investors, and business aspirants. The macro and microeconomic factors with substantive Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) insights are analyzed in this study.

All the above queries are effectively addressed by the analyst team of Reportscheck.com. Also, custom reports are available based on the client's requirements. Analyst views and opinions about the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry with qualitative and quantitative inputs will lead to sound business plans. The investment feasibility check, the latest innovations, developments, raw materials, and Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) consumer demand analysis is conducted. The competitive dashboard reflects the top companies' analysis, growth rate, revenue, market share, product portfolio, and the latest developments.

Development trends, competitive analysis, and growth dynamics are key aspects of this report

Past, present, and forecast Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry evaluation with complete performance monitoring of top players,.

Each product type and application regional and country-level bifurcation offer comprehensive and niche Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) analysis

The product portfolio, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) company profiles, SWOT, and Porters Five Forces analysis offers quality inputs

Pre and Post pandemic situations, ways to overcome pandemic, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) developments across different macro and micro-segments are analyzed

Market size, product pricing analysis, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) cost structures, raw material, and downstream buyers analysis is conducted

In-depth primary and secondary techniques applied by Reports Check provide quality, reliability, thorough analysis, and competitive market intelligence

Forecast regional, country-level dynamics, expected growth rate, revenue generation, upcoming segments, and Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) vendors, R&D status is specified

Browse our recently released reports here:https://www.reportscheck.com/shop/2021-2026-report-on-global-circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market-by-player-region-type-application-and-sales-channel/

Contact Us:

Olivia Martin

Marketing Manager

Email: [emailprotected]

Website:www.reportscheck.com

Continued here:
2020 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Competitive Research, Top Companies, Key Types, Revenue, Share, Size...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market – Growth, Trends, and Forecast (2020 – 2025) – GlobeNewswire

September 22, 2020 04:03 ET | Source: ReportLinker

New York, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Autologous Stem Cell and Non-Stem Cell Based Therapies Market - Growth, Trends, and Forecast (2020 - 2025)" - https://www.reportlinker.com/p05974135/?utm_source=GNW

- Stem cell technology is found to be a speedily developing technology which plays a major role in regenerative medicine, as it also serves the disciplines of tissue engineering, developmental cell biology, cellular therapeutics, gene therapy, chemical biology, and nanotechnology. Stem cells offer the possibility of replacing the cells and tissues to treat various conditions including spinal cord injury, arthritis, and Parkinsons disease, among others. - The applications of stem cell technologies in the treatment of diseases have ultimately increased the overall adoption rate of these technologies across the world. - The advantage of autologous stem cell transplant is that one is getting ones own cells back. This means there is no risk that the immune system of the individual will reject the transplant or that the transplanted cells will attack or reject the individuals body.

Key Market Trends Cancer Holds Significant Share in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market

- Cancer rates could further increase by 50%, to 15 million new cases by 2020, as per World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners could stem this trend, and prevent as many as one-third of cancers, worldwide. - The American Cancer Society, the leading body in cancer stats and figures, reports 1,685,210 estimated new cancer cases and 595,690 deaths due to cancer in 2016, in the United States. - The National Cancer Institute reports that more than 60% of the worlds new cancer cases occur in Africa, Asia, and Central and South America; 70% of the worlds cancer deaths also occur in these regions. The International Agency for Research on Cancer (IARC) predicts that by 2030, the global burden is expected to rise to 21.7 million new cancer cases and 13 million cancer deaths, simply due to growth and aging of population, leaving aside factors, such as smoking, poor diet, physical inactivity, and fewer childbirths in economically developing countries. - According to WHO, almost 70% of deaths from cancer occur in low and middle-income countries, and only one in five low- and middle-income countries has the necessary data to drive cancer policy. This global and extensive threat of cancer remains a major market driver for new cancer therapies that help in risk assessment, early diagnosis, and effective monitoring of the treatment.

North America Dominates the Autologous Stem Cell and Non-Stem Cell Based Therapies Market

- North America dominated the overall stem cell market with the United States contributing to the largest share in the market. - The ease in the US government regulations and availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in the use of biomarkers in drug discovery, drug development, detection of specific tumors, monitoring biological response to cancer therapy, and genetic studies for the identification of predisposed candidates of cancer. - In 2014, the Sanford Stem Cell Clinical Center at the University of California, San Diego (UCSD) Health System, announced the launch of a clinical trial, in order to assess the safety of neural stem cellbased therapy in patients with chronic spinal cord injury. - Researchers hoped that the transplanted stem cells may develop into new neurons that could replace severed or lost nerve connections, and restore at least some motor and sensory functions. Such numerous stem cell studies across the United States have helped in the growth of the stem cell market.

Competitive Landscape The global Autologous Stem Cell and Non-Stem Cell-Based Therapies market is competitive and consists of a few major players. The companies includes Novartis AG, BrainStorm Cell Limited, Caladrius, Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences Inc., Regeneus Ltd, U.S. Stem Cell, Inc, among others, hold the substantial market share in the growth of overall market.

Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format - 3 months of analyst support Read the full report: https://www.reportlinker.com/p05974135/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market - Growth, Trends, and Forecast (2020 - 2025) - GlobeNewswire

OncoImmune’s SACCOVID (CD24Fc) Exhibits Superb Therapeutic EfficacyA Potential Breakthrough in Treating Severe and Critical COVID-19 – Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--OncoImmune Inc. today announced that it has closed enrollment of the Phase III SAC-COVID clinical trial (NCT04317040) and releases topline results from the pre-planned interim efficacy analysis. Data from 203 participants (75% of the planned enrollment) show that severe or critical COVID-19 patients treated with SACCOVIDTM exhibited significantly faster recovery and significantly reduced disease progression to death or respiratory failure than those receiving placebo, when used in conjunction with the standard of care (SOC).

The SAC-COVID Phase III clinical trial is randomized, placebo-controlled and blinded to participants, the clinical teams, the investigators, and the Sponsor. Hospitalized COVID-19 patients who required oxygen support, including those requiring supplemental oxygen, high flow oxygen, and non-invasive ventilation were randomly assigned into two arms receiving either SOC plus a single dose of SACCOVIDTM or SOC plus placebo. The trial had a planned enrollment of 270 patients. The pre-specified interim efficacy and safety analyses were performed when 146 patients achieved clinical recovery from COVID-19, a milestone achieved with 203 enrollments. The trial was opened in April this year and was activated in 15 medical centers in the US.

The interim analysis shows safety and outstanding therapeutic efficacy of SACCOVIDTM. The results indicate that patients who received SACCOVIDTM had a 60% better chance to achieve clinical recovery than those who received placebo (P=0.005). The median time to recovery was 6 days for patients treated with SACCOVIDTM compared with 10 days in the placebo group. In addition, the risk of death or respiratory failure is reduced by more than 50%, said Dr. Pan Zheng, MD, PhD, Chief Medical Officer and co-founder of OncoImmune. Since the trial did not exclude other experimental therapeutics, many participants also received Remdesivir and/or corticosteroids including dexamethasone. Among them, those who were treated with SACCOVIDTM and Remdesivir recovered 7 days earlier than those who received Remdesivir and placebo (median time to recovery 6 days vs 13 days). Those who were treated with SACCOVIDTM and corticosteroids recovered 10 days earlier than those who received corticosteroids and placebo (median time to recovery 5 days vs 15 days). More detailed information about the trial results will be released as soon as the study is submitted to peer-reviewed medical journals.

The very large therapeutic effect of SACCOVIDTM observed potentially represents a major breakthrough in COVID-19 therapy. We took a novel approach to fortify an innate immune checkpoint we discovered, having previously demonstrated efficacy in a nonhuman primate model for treating viral pneumonia, and applied this to SARS-CoV-2. We are exhilarated that this approach appears to have led to unparalleled efficacy. OncoImmune is focusing on expanding drug supply and regulatory approval to make the drug available to COVID-19 patients, said Yang Liu, PhD, Co-founder and Chief Executive Officer.

SACCOVIDTM (known as CD24Fc during its development by OncoImmune, Inc.), is an investigational immunomodulator targeting the innate immune system. CD24Fc has been studied for safety in healthy volunteers and in Phase II clinical trials for the prevention of graft versus host disease (GVHD) following hematopoietic stem cell transplantation in leukemia patients, where it also showed therapeutic efficacy. The Phase III SAC-COVID clinical trial is partially funded through a grant from the National Cancer Institute.

About OncoImmune, Inc.

OncoImmune (www.oncoimmune.com) is a privately-held, clinical-stage biopharmaceutical company focusing on the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases. OncoImmune is based in Rockville, Maryland.

OncoImmunes lead program, CD24Fc, develops novel therapeutic products based on CD24Fc that regulates host inflammatory response to tissue injuries and may have broadly applicable to cancer, autoimmune disease, metabolic syndrome and graft-versus-host disease (GVHD). OncoImmune has completed a Phase IIa trial using CD24Fc to treat leukemia patients undergoing hematopoietic stem cell transplantation (HSCT). The data from the trial suggest a significant improvement in 180 Day Grade III-IV acute GVHD-Free Survival, the primary endpoint for the Phase III clinical trial called CATHY. CD24Fc prophylaxis also resulted in reduced Relapse and demonstrated improvement in Overall Survival, Non-Relapse Mortality and Relapse-Free Survival, as compared with the controls. A dose-dependent reduction in severe (Grade > 3) mucositis was also observed. A 20 patients open label dose expansion cohort at the recommended clinical dose has been fully enrolled and the CD24Fc continues to perform very well. The Phase III study for the prevention of aGVHD is being initiated nationwide. The CD24Fc programs have been partially funded by the National Institutes of Health and the Food and Drug Administrations.

View post:
OncoImmune's SACCOVID (CD24Fc) Exhibits Superb Therapeutic EfficacyA Potential Breakthrough in Treating Severe and Critical COVID-19 - Business Wire

Cell Therapy Market – Global Size, Share, Trends and Key Players (2020-2025) – News by aeresearch

The report, titled Cell Therapy Market, is a comprehensive document that provides valuable insights into market elements like drivers, restraints, competitive landscape, and technology evolution. For a better understanding of the market, the report offers a comprehensive analysis of the key segments and future growth prospects. The current COVID-19 pandemic has significantly changed market dynamics and the global economy. The report provides an impact analysis of the pandemic on the entire market. It also provides an analysis of the current and future impact. The report provides a comprehensive analysis of the dynamic changes in trends and requirements due to the COVID-19 pandemic. The report also includes a post-COVID scenario and prospects for future growth.

The research report on Cell Therapy market encloses a complete examination of present and future scenario of this industry domain. It mentions the growth driving factors and opportunities which will help in industry expansion, as well as the challenges that will hamper the market growth.

The report offers historic as well as current data on various market segmentations to determine key products, applications, and end-users impacting the business revenue. It also highlights and market share and growth rate of the industry over the analysis period. Besides, the study contains pricing models and consumption patterns of this business space.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/311593

Questions about the regional terrain that are answered in the Cell Therapy market report:

Other vital pointers in the Cell Therapy market report:

Key Reasons to Purchase

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/311593

Continue reading here:
Cell Therapy Market - Global Size, Share, Trends and Key Players (2020-2025) - News by aeresearch

Former NFL star Eddie George returns to Vero Beach for therapy, this time on shoulder – TCPalm

Eddie George was in Vero Beach, Florida, on September 19, 2020, for a medical procedure and discussed the return of Big 10 football. Gannett Staff

VERO BEACH Stem cell and plasma therapy brought a former NFL player to Vero Beach to soothe his ailing knees a few years ago.

Now, he's just looking for a good night's sleep, all because of a nagging shoulder injury. And the same specialists in Vero said they could help him with that, too.

On Saturday, Eddie George, who was a Heisman Trophy winner at Ohio State University and one of the initial stars of the Tennessee Titans, made another trip to Regenerative Biologistics Institute in Vero Beach for treatment. The first time, in July 2018, was to help his knees.

"Walking was a chore,let alone trying to jog," said George, 47, who still lives in the Nashville area.

But now he's walking, swimming and doing enough exercise that he returned to the institute Saturday lighter than he was previously. George said he lost 20 pounds this year.

"My joints have been great," said the now 244-pound, 6-feet-3 former athlete. "I feel a lot better."

Former professional football player Eddie George shares a laugh with regenerative medicine specialists Jason Griffeth (left) and Brett Haake on Saturday, Sept. 19, 2020, as he prepares to receive stem cell and growth factor injections in both knees and right shoulder at Regenerative Biologics Institute in Vero Beach. "What the injections will do is decrease inflammation, decrease pain and increase functionality," said Haake, medical director for the institute. "We're focusing on longevity. We're focusing on optimizing someone's functionality and minimizing their morbidity. We focus on prevention and intervening disease states earlier rather than later." George suffered several injuries during his time playing football.(Photo: PATRICK DOVE/TCPALM)

What doesn't feel better is a shoulder injury he has had since his freshman year with the Ohio State Buckeyes. George chose to have a stem cell injection inhis shoulder Saturday.

"There's a piece missing from my right shoulder socket," George said. "The integrity of the joint there has been compromised. I don't have a lot of flexibility there. When I sleep at night, it gets aggravated and I have to constantly move to get adjusted."

RBI Medical Director Dr. Brett Haake also gave George more injections to his knees Saturday. George had surgery on one of them in March to remove bone spurs.

The institute isat 3755 Seventh Terrace, just north of the Cleveland Clinic Indian River Hospitalin Vero Beach. Clinical director Jason Griffeth said his office uses Regenmax Injection Therapy, which transfers stem cells from a person's abdomen to parts of the body where the patient is feeling pain.

The regenerative abilities of the stem cells repair the injured tissue in areas lacking those cells, said Griffeth, whose office opened in 2016.

"The stem cells areanti-inflammatory and very regenerative," Haake said.

More: SWV star Taj George gets stem cell treatment for knees in Vero Beach

George's R&B star wife, Tamara "Taj" George of the group SWV, also had the procedure done on her knees last year. She said years on stage have damaged her knees, but the stem cell therapy allows her to run now.

"I gained a little bit of weight during this quarantine, but I'm still able to run," she said in a phone call Saturday.

Eddie George is recommending the procedure to other athletes, active or retired.

"This can prolong their careers and their lifestyle after they're done playing," he said.

Autoplay

Show Thumbnails

Show Captions

In retirement, George runs a wealth management company and will be commenting on college football on ESPN's XM Satellite Radio station a few days a week, he said.

The institute recommends its therapy for arthritis, torn rotator cuffs, meniscus injuries and bursitis.

On the web: rbistemcell.com

More: Miami Dolphins to allow 13,000 fans to home opener vs. Bills at Hard Rock Stadium

LamaurStancilis the Treasure Coast regional economy reporter covering businessand industries, including retail, tourism and hospitality.Contact him at 321-987-7179 orlamaur.stancil@tcpalm.com and follow him at Lamaur Stancil on Facebook and @TCPalmLStancil on Twitter.

To stay up to date with ourexclusive content, be sure tosubscribe.

Read or Share this story: https://www.tcpalm.com/story/news/local/indian-river-county/2020/09/20/ex-nfl-star-eddie-george-returns-vero-beach-therapy-shoulder/5823079002/

View post:
Former NFL star Eddie George returns to Vero Beach for therapy, this time on shoulder - TCPalm